Patients with rheumatoid arthritis starting bDMARDs have higher ILD risk vs those with PsA
Patients with rheumatoid arthritis or psoriatic arthritis starting biologic disease-modifying antirheumatic drugs have a higher risk for interstitial lung disease vs. the general population, with the highest risk found in RA, data show.The study, published in The Journal of Rheumatology, additionally found that adding methotrexate to biologic DMARD treatment did not increase either group’s